Peter Choyke

Identification of the von Hippel-Lindau Disease Tumor Suppressor Gene

Farida Latif, Kálmán Tory, James R. Gnarra et al. · Science · 1993 · 3K citations

Medicine, Genetics, Molecular Genetics +17

Pilot trial of EZN-2968, an antisense oligonucleotide inhibitor of hypoxia-inducible factor-1 alpha (HIF-1α), in patients with refractory solid tumors

Woondong Jeong, Annamaria Rapisarda, Sook Ryun Park et al. · Cancer Chemotherapy and Pharmacology · 2013 · 156 citations · Full text

Medicine, Oncology, Pharmacology +14

A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma

Jame Abraham, Susan Bakke, Ann Rutt et al. · Cancer · 2002 · 120 citations

Medicine, Oncology, Pharmacology +15

A Phase I study of infusional vinblastine in combination with the p-glycoprotein antagonist PSC 833 (valspodar)

Susan E. Bates, Min H. Kang, Beverly Meadows et al. · Cancer · 2001 · 80 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +15

Von Hippel-Lindau (VHL) disease: distinct phenotypes suggest more than one mutant allele at the VHL locus

G.M. Glenn, Lambert N. Daniel, Peter Choyke et al. · Human Genetics · 1991 · 75 citations

Life Sciences, Genetics, Molecular Genetics +14